SynthesisEuropean journal of clinical pharmacology2022
Factors predicting clinical and endoscopic remission with placebo therapy in East Asian patients with ulcerative colitis: a systematic review and meta-analysis.
Synthesis in European journal of clinical pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Placebo rates in randomized clinical trials of ulcerative colitis: an individual patient data meta-analysis.Journal of Crohn's & colitis · 2025Pooled it
- What the Patient Thinks and What the Patient Does: Placebo, Nocebo, and Therapy Adherence in Ulcerative Colitis.Journal of clinical medicine · 2025Review
- Natural flavones from edible and medicinal plants exhibit enormous potential to treat ulcerative colitis.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe placebo effect in randomized controlled trials (RCTs) for East Asian patients with ulcerative colitis (UC) has been poorly characterized. This systematic review and meta-analysis aimed to determine the placebo rates of clinical and endoscopic remission in East Asian patients with UC and to identify factors that influenced placebo outcomes.
methodsA comprehensive search was performed to identify all eligible RCTs. The placebo rates of clinical and endoscopic remission were pooled by random effects. Univariate meta-regression was performed to evaluate the influence of different factors on these placebo rates.
resultsFourteen induction and seven maintenance RCTs were included, comprising 1781 East Asian patients with UC. The pooled placebo rates of clinical and endoscopic remission for induction trials were 13% (95% confidence interval [CI] 10-16%) and 26% (95% CI 21-32%), respectively. Corresponding values for maintenance trials were 15% (95% CI 10-23%) and 24% (95% CI 19-29%). Heterogeneity existed among the studies. On univariate meta-regression, the route of drug administration, outcome definition, disease severity, disease duration, distal disease and concomitant corticosteroids influenced the outcomes of placebo arms.
conclusionsThe placebo rates of clinical and endoscopic remission in RCTs for East Asian patients with UC range from 13 to 26%, and are influenced by specific study characteristics. These results can inform the design and interpretation of future clinical trials in this region.
Indexed as
Identifiers
35347342What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.